Hu Weini, Zhang Tianhong, Zhang Yinghong, Meng Chao, Xie Lifeng, Song Yu, DU Chen, Xu Chiyu, DU Yali, Zuo Qiang, An Fengyang, Wang Yuhui, Meng Cuida, Zhang Lei, Zhu Dongdong, Zhu Li
Department of Otolaryngology Head and Neck Surgery，Peking University Third Hospital，Beijing，100191，China.
Department of Otolaryngology Head and Neck Surgery，the First Affiliated Hospital of Harbin Medical University.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023 Jul;37(7):550-555. doi: 10.13201/j.issn.2096-7993.2023.07.008.
To observe the efficacy and safety of the M receptor antagonist Bencycloquidium bromide nasal spray in treatment of seasonal allergic rhinitis with runny nose as the main symptom. From August 2021 to September 2021, 134 patients with seasonal allergic rhinitis were enrolled in the otolaryngology Outpatient Department of Peking University Third Hospital, First Affiliated Hospital of Harbin Medical University and China-Japanese Friendship Hospital of Jilin University, including 71 males and 63 females, with a median age of 38 years. TNSS score and visual analogue scale（VAS） of total nasal symptoms were observed during 2 weeks of treatment with Bencycloquidium bromide nasal spray. TNSS score decreased from （8.89±3.31） on day 0 to （3.71±2.51） on day 14（<0.001）, VAS score of nasal symptoms decreased from （24.86±7.40） on day 0 to （6.84±5.94） on day 14（<0.001）, VAS score of rhinorrhoea decreased from （6.88±2.06） on day 0 to （1.91±1.81） on day 14（<0.001）. Rhinoconjunctivitis quality of life questionnaire（RQLQ） score decreased from （94.63±33.35） on day 0 to （44.95±32.28） on day 14（<0.001）. The incidence of adverse reaction was low and no serious adverse events occurred during the whole experiment. Bencycloquidium bromide nasal spray has significant efficacy and good safety in the treatment of seasonal allergic rhinitis.
观察M受体拮抗剂溴苯环喹酯鼻喷雾剂治疗以流涕为主要症状的季节性变应性鼻炎的疗效及安全性。2021年8月至2021年9月，北京大学第三医院耳鼻咽喉科门诊、哈尔滨医科大学附属第一医院及吉林大学中日联谊医院共纳入134例季节性变应性鼻炎患者，其中男性71例，女性63例，年龄中位数为38岁。在使用溴苯环喹酯鼻喷雾剂治疗的2周内观察总鼻症状评分（TNSS）和总鼻症状视觉模拟量表（VAS）。TNSS评分从第0天的（8.89±3.31）降至第14天的（3.71±2.51）（<0.001），鼻症状VAS评分从第0天的（24.86±7.40）降至第14天的（6.84±5.94）（<0.001），流涕VAS评分从第0天的（6.88±2.06）降至第14天的（1.91±1.81）（<0.001）。变应性鼻炎生活质量问卷（RQLQ）评分从第0天的（94.63±33.35）降至第14天的（44.95±32.28）（<0.001）。不良反应发生率低，整个实验期间未发生严重不良事件。溴苯环喹酯鼻喷雾剂治疗季节性变应性鼻炎疗效显著，安全性良好。
